MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. reported a Q2 2026 net loss of $3.1 million, narrower than $4.2 million a year earlier, as research and development expense was $1.9 million and general and administrative expense declined to $1.3 million. For the first six months, net loss was $5.9 million versus $7.0 million in 2025.
Cash and cash equivalents were $8.8 million at June 30, 2026, after using $3.8 million in operating cash and repaying a $5.0 million related-party convertible note in January 2026. The company raised $4.4 million by selling 313,478 shares under its at-the-market equity program, with $30.6 million of capacity remaining.
Accumulated deficit reached $162.5 million, and MiNK reported stockholders’ deficit of $14.0 million alongside $16.1 million due to related parties that Agenus has agreed not to call for repayment for the foreseeable future. Management states that, despite expected funding, substantial doubt exists about the company’s ability to continue as a going concern for one year after the report date.
MiNK Therapeutics, Inc. reported second quarter 2026 results and clinical progress for its lead iNKT cell therapy, agenT-797. Cash and cash equivalents were $8.8 million as of June 30, 2026. Net loss for the quarter was $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, in the second quarter of 2025. For the first six months of 2026, net loss was $5.9 million, or $1.20 per share, versus $7.0 million, or $1.76 per share, a decrease attributed to expense discipline.
Clinically, MiNK reported initial Day 28 observations from its randomized Phase 2 trial C-1300-02 of agenT-797 in acute lung injury/ARDS, with treated patients alive at Day 28, improved oxygenation, infection control, and no major serious adverse events attributed to agenT-797 in these initial patients. The company also launched a paid, per-patient, physician-initiated named-patient access program for agenT-797 in Brazil, which may generate non-promotional revenue while expanding access under regulatory oversight.
MiNK Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 17, 2026. A total of 3,277,906 shares of common stock were present in person or by proxy, representing 65.79% of shares outstanding and establishing a quorum.
Stockholders elected Garo Armen, Barbara Ryan and John Holcomb as Class II directors for three-year terms ending at the 2029 annual meeting. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
MiNK Therapeutics director Barbara Ryan reported selling a total of 1,500 shares of Common Stock in open-market transactions. The sales on June 4, 2026 were executed at prices of $12.7995 for 1,000 shares and $12.6835 for 500 shares. Following these transactions, she directly holds 21,969 shares of MiNK Therapeutics common stock. According to the filing, the shares sold had been received as compensation for services as a member of the company’s Board of Directors.
Holcomb John Bradley reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics, Inc. director John Bradley Holcomb reported two stock-based compensation grants. On June 1, 2026, he received 1,091 shares of Common Stock as restricted stock units (RSUs) valued at $12.38 per share in lieu of cash board and committee retainers.
On March 2, 2026, he received an additional 1,239 RSU-based shares at $10.90 per share for Q1 2026 service. The filing notes these Q1 RSUs were not filed earlier due to an administrative error. After these awards, he directly holds 3,458 shares of MiNK Therapeutics common stock. The RSUs vest one month after each grant date, reflecting routine non-cash director compensation rather than open-market purchases.